Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Artificial Intelligence In Vitro Diagnostics Coronavirus COVID-19

Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests

Executive Summary

Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.

You may also be interested in...



Novartis Heart Health Catalyst Announces Dual Winners

PocDoc and Lifelight have won the Novartis’ Heart Health Catalyst program and will work on smartphone-based lipid-measuring and clinical vital signs tools for evaluating cardiac health on a population level.

Not All AI Companies Are A Success: The Woes Of Sensyne

The business founded by Lord Drayson has struggled to achieve commercial success for its artificial intelligence products.

Spanish Team’s AI Model For Pandemic Response Named XPRIZE Winner

VALENCIA IA4COVID19’s AI model won the XPRIZE Pandemic Response Challenge grand prize. Researchers are pinning their hopes on AI to help predict the next pandemic, but also for early diagnosis of COVID-19.

Table

View full table

Related Content

Medtech Insight
Scrip
In Vivo
Scrip
Medtech Insight

Topics

Related Companies

Tags:
Artificial Intelligence In Vitro Diagnostics Coronavirus COVID-19
Latest News

Council Of EU Supports Urgent MDR Action By European Commission

Chinese Firms Recalls Unauthorized DNA/RNA Preservation Kits, FDA Labels The Action Class I

Human Factors Guidance Provides Clarity On Data Necessary In Premarket Submissions

Cancer Testing Industry Will Benefit As EU Accepts Need To Modernize Screening

See All
UsernamePublicRestriction

Register

MT143461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By